Filter:
Tested Applications
| Positive WB detected in | human brain tissue, NCI-H1299 cells, A549 cells |
| Positive IHC detected in | human spleen tissue Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0 |
| Positive IF/ICC detected in | A549 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 |
| Immunohistochemistry (IHC) | IHC : 1:20-1:200 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
20564-1-AP targets PAFAH1B3 in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Cited Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | platelet-activating factor acetylhydrolase, isoform Ib, gamma subunit 29kDa |
| Calculated Molecular Weight | 26 kDa |
| Observed Molecular Weight | 26-29 kDa |
| GenBank Accession Number | NM_002573 |
| Gene Symbol | PAFAH1B3 |
| Gene ID (NCBI) | 5050 |
| RRID | AB_10693534 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | Q15102 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
PAFAH1B3, also named as PAFAHG, belongs to the 'GDSL' lipolytic enzyme family and Platelet-activating factor acetylhydrolase IB beta/gamma subunits subfamily. It inactivates paf by removing the acetyl group at the sn-2 position. This is a catalytic subunit. PAFAH1B3 plays an important role during the development of brain. The antibody is specific to PAFAH1B3.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| IHC protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| WB protocol for PAFAH1B3 antibody 20564-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
| Species | Application | Title |
|---|---|---|
Onco Targets Ther Aberrant expression of PAFAH1B3 associates with poor prognosis and affects proliferation and aggressiveness in hypopharyngeal squamous cell carcinoma.
| ||
Discov Oncol Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma | ||
Discov Oncol Increased PAFAH1B3 was associated with poor prognosis and T-cell exhaustion microenvironment in hepatocellular carcinoma | ||
Int J Mol Sci PAFAH1B3 Exists in Linear Chromosomal and Extrachromosomal Circular DNA and Promotes HCC Progression via EMT.
| ||
Biochem Pharmacol PAFAH1B3 promotes gastric cancer progression by enhancing E2F8-mediated transcriptional activation of VEGFA expression. |
